Increased signalling through the insulin-like growth factor (IGF) pathway has been implicated in the progression of several types of human cancer. The ICF2 ligand is frequently overexpressed in colon and breast cancers, and inhibitors of one its receptors, IGF1 receptor (IGF1R), are in clinical trials. However, Ulanet et al. now demonstrate that IGF2 signalling through a second receptor-insulin receptor (INSR) - can contribute to tumorigenesis and intrinsic resistance to anti-IGFIR therapy.
展开▼
